141 related articles for article (PubMed ID: 25363327)
1. Reply: To PMID 25098971.
Guedj J; Canini L; Cotler S; Dahari H
Hepatology; 2015 Jun; 61(6):2118-9. PubMed ID: 25363327
[No Abstract] [Full Text] [Related]
2. Effect of interferon-alpha therapy on hepatitis D virus.
Goyal A; Murray JM
Hepatology; 2015 Jun; 61(6):2117-8. PubMed ID: 25363368
[No Abstract] [Full Text] [Related]
3. Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling.
Guedj J; Rotman Y; Cotler SJ; Koh C; Schmid P; Albrecht J; Haynes-Williams V; Liang TJ; Hoofnagle JH; Heller T; Dahari H
Hepatology; 2014 Dec; 60(6):1902-10. PubMed ID: 25098971
[TBL] [Abstract][Full Text] [Related]
4. Current management of delta hepatitis.
Rizzetto M
Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
Dimova RB; Talal AH
J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
[No Abstract] [Full Text] [Related]
6. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
Ouzan D; Pénaranda G; Joly H; Halfon P
J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
[No Abstract] [Full Text] [Related]
7. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
[TBL] [Abstract][Full Text] [Related]
8. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
[TBL] [Abstract][Full Text] [Related]
9. Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection?
Scholtès C; Kumar R; Zoulim F
Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2350-2. PubMed ID: 26254201
[No Abstract] [Full Text] [Related]
10. Peginterferon and ribavirin for chronic hepatitis C.
Hoofnagle JH; Seeff LB
N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
[No Abstract] [Full Text] [Related]
11. Reply to issues raised in the Jansen/Reesink editorial.
Silva M
J Hepatol; 2007 Feb; 46(2):350-1. PubMed ID: 17161883
[No Abstract] [Full Text] [Related]
12. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa--authors' reply.
Koh C; Heller T
Aliment Pharmacol Ther; 2015 Mar; 41(6):595-6. PubMed ID: 25659215
[No Abstract] [Full Text] [Related]
13. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of interferon-stimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection.
Han M; Li Y; Wu W; Zhang Y; Yan W; Luo X; Ning Q
Antiviral Res; 2017 Nov; 147():75-85. PubMed ID: 28988797
[TBL] [Abstract][Full Text] [Related]
15. Treatment of chronic hepatitis D patients with pegylated interferon: a real-world experience.
Abbas Z; Memon MS; Mithani H; Jafri W; Hamid S
Antivir Ther; 2014; 19(5):463-8. PubMed ID: 24423484
[TBL] [Abstract][Full Text] [Related]
16. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
[TBL] [Abstract][Full Text] [Related]
17. Peginterferon plus adefovir versus either drug alone for hepatitis delta.
Wedemeyer H; Yurdaydìn C; Dalekos GN; Erhardt A; Çakaloğlu Y; Değertekin H; Gürel S; Zeuzem S; Zachou K; Bozkaya H; Koch A; Bock T; Dienes HP; Manns MP;
N Engl J Med; 2011 Jan; 364(4):322-31. PubMed ID: 21268724
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response.
Samiullah S; Bikharam D; Nasreen
World J Gastroenterol; 2012 Oct; 18(40):5793-8. PubMed ID: 23155322
[TBL] [Abstract][Full Text] [Related]
19. Letter: the potential success of long-term therapy of chronic delta hepatitis with peginterferon alfa.
Maraolo AE; Minervini F; Tosone G
Aliment Pharmacol Ther; 2015 Mar; 41(6):595. PubMed ID: 25659214
[No Abstract] [Full Text] [Related]
20. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
